Announcements
- Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
- Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
- Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
- Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
- Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
- Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
More ▼
Key statistics
As of last trade Vericel Corp (ATQP:DUS) traded at 46.40, -4.53% below its 52-week high of 48.60, set on Apr 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 46.40 |
---|---|
High | 46.40 |
Low | 46.40 |
Bid | 46.60 |
Offer | 48.00 |
Previous close | 46.20 |
Average volume | 5.56 |
---|---|
Shares outstanding | 48.60m |
Free float | 48.14m |
P/E (TTM) | 5,410.04 |
Market cap | 2.51bn USD |
EPS (TTM) | 0.0096 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 08:31 BST.
More ▼